moxifloxacin has been researched along with amoxicillin-potassium clavulanate combination in 41 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (amoxicillin-potassium clavulanate combination) | Trials (amoxicillin-potassium clavulanate combination) | Recent Studies (post-2010) (amoxicillin-potassium clavulanate combination) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,827 | 612 | 1,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (48.78) | 29.6817 |
| 2010's | 20 (48.78) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Flores, SM; Heyd, A; Rakkar, S; Roberts, K; Towe, BF; Warner, J | 1 |
| Bobbaers, H; Collins, O; Finch, R; Hoeffken, G; Izquierdo, JL; Kubin, R; McGivern, J; Nikolaides, P; Ogundare, F; Raz, R; Schürmann, D; Zuck, P | 1 |
| Becker, DL; Chancellor, JV; Drummond, MF; Duprat-Lomon, I; Hux, M; Kubin, R; Sagnier, PP | 1 |
| Bassaris, H; Gogos, CA; Starakis, I | 1 |
| Ardanza-Trevijano, B; Canut, A; Isla, A; Labora, A; Pedraz, JL; Rodríguez-Gascón, A; Solinís, MA | 1 |
| Brambilla, C; Garre, M; Paganin, F; Portier, H; Poubeau, P; Zuck, P | 1 |
| Cots, JM; Llor, C; Miravitlles, M; Molina, J; Naberan, K | 1 |
| Giordano, P; Herrington, J; Kowalsky, S; Pertel, P; Song, J | 1 |
| Bolaños, M; Finegold, SM; Molitoris, D; Väisänen, ML | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Ednie, L; Lin, G; Shapiro, S; Smith, K | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Choudhri, S; Herrington, J; Malangoni, MA; Pertel, P; Song, J | 1 |
| Claeys, G; Delmée, M; Glupczynski, Y; Gordts, B; Ieven, M; Lauwers, S; Melin, P; Piérard, D; Reynders, M; Struelens, M; Vandoorslaer, K; Verhaegen, J; Verschraegen, I; Wybo, I | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
| Alvarez, M; Diz, P; Limeres, J; Potel, C; Tomás, I; Tomás, M; Velasco, D | 1 |
| Denizbasi, A; Erdede, M; Guneysel, O; Onur, O | 1 |
| Al-Nawas, B; Krummenauer, F; Maeurer, M; Morbach, T; Seitner, N; Siegel, E; Walter, C | 1 |
| Diz, P; Limeres, J; Sanromán, JF; Tomás, I | 1 |
| Hampel, B; Lippert, H; Muehlhofer, E; Reimnitz, P; Weiss, G | 1 |
| Kaczmarzyk, T | 1 |
| Ardila, CM; Fernández, N; Guzmán, IC | 1 |
| Ardila, CM; Granada, MI; Guzmán, IC | 1 |
| Aracil, B; Campos, J; Cuevas, O; de Abajo, F; García-Cobos, S; Lázaro, E; Ortega, A; Oteo, J | 1 |
| Al-Nawas, B; d'Hoedt, B; Karbach, J; Mouratidou, A | 1 |
| Anzueto, A; Arvis, P; Faragó, G; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Hampel, B; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, N | 1 |
| Alder, J; Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R | 2 |
| Balzer, L; Böger, RH; Cachovan, G; Giersdorf, I; Haddad, M; Hallier, O; Platzer, U; Sobottka, I; Streichert, T; Wegscheider, K | 1 |
| Boersma, WG | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Conget, F; de la Roza, C; Domenech, A; García-Polo, C; Miravitlles, M; Villegas, G | 1 |
| Alcántara, F; Atwood, SS; Becerra, MC; Bonilla, CA; Mitnick, CD; Seung, KJ | 1 |
| Achiraman, S; Anandhakumar, S; Antony, JJ; Raichur, AM; Siva, D; Sripriya, J | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Mattappallil, A; Mergenhagen, KA; Ott, MC; Ruh, CA; Schroeck, JL; Sellick, JA | 1 |
| Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R | 1 |
| Criollo, M; DiCasoli, C; Digtyar, V; Emil, SGS; Engelis, A; Grossmann, U; Nkulikiyinka, R; Stass, H; Willmann, S; Wirth, S | 1 |
| Bosc, R; Chosidow, O; De Prost, N; Hua, C; Hughes, C; Jabre, P; Le Cleach, L; Sbidian, E | 1 |
| Kurz, X; McGettigan, P; Morales, D; Pacurariu, A; Pinheiro, L; Slattery, J | 1 |
| Attin, T; Bensland, S; Eick, S; Karygianni, L; Kulik, EM; Thurnheer, T | 1 |
2 review(s) available for moxifloxacin and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
[Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology].
Topics: Algorithms; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Bacterial Infections; Clindamycin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Fusobacterium nucleatum; Humans; Microbial Sensitivity Tests; Mouth Diseases; Moxifloxacin; Peptostreptococcus; Periodontitis; Porphyromonas gingivalis; Prevotella intermedia; Quinolines; Time Factors; Viridans Streptococci | 2005 |
Interventions for necrotizing soft tissue infections in adults.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; CD28 Antigens; Critical Care; Debridement; Female; Fluoroquinolones; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Moxifloxacin; Randomized Controlled Trials as Topic; Soft Tissue Infections | 2018 |
19 trial(s) available for moxifloxacin and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome | 2001 |
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |
Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Bronchitis, Chronic; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Sputum; Treatment Outcome | 2004 |
Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Roxithromycin | 2005 |
Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Drug Therapy, Combination; Epidemiologic Methods; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Oxygen Inhalation Therapy; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2005 |
Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Tolerance; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Skin Diseases, Bacterial | 2005 |
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Topics: Abdominal Abscess; Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendicitis; Aza Compounds; Bacterial Infections; Cross Infection; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Intestinal Perforation; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Stomach Rupture; Treatment Outcome | 2006 |
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Moxifloxacin; Periodontal Abscess; Pilot Projects; Prospective Studies; Quinolines; Time Factors; Treatment Outcome | 2009 |
Patients' perception of recovery after third molar surgery following postoperative treatment with moxifloxacin versus amoxicillin and clavulanic acid: a randomized, double-blind, controlled study.
Topics: Adolescent; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Molar, Third; Moxifloxacin; Osteitis; Prospective Studies; Quality of Life; Quinolines; Recovery of Function; Sickness Impact Profile; Tooth Extraction; Tooth, Impacted; Young Adult | 2009 |
Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Topics: Abdominal Abscess; Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Appendicitis; Aza Compounds; Bacterial Infections; Ceftriaxone; Drug Therapy, Combination; Female; Fluoroquinolones; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Intestinal Perforation; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Peritonitis; Prospective Studies; Quinolines | 2009 |
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.
Topics: Adrenal Cortex Hormones; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bronchodilator Agents; Canada; Double-Blind Method; Drug Therapy, Combination; Europe; Fluoroquinolones; Humans; Lung; Moxifloxacin; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Research Design; Severity of Illness Index; Time Factors; Treatment Outcome; United States | 2011 |
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines; Skin; Skin Diseases, Bacterial | 2011 |
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2012 |
Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Clindamycin; Culture Media; Double-Blind Method; Female; Fluoroquinolones; Germany; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Outpatients; Penicillins; Periodontal Abscess; Prospective Studies; Quinolines | 2012 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.
Topics: Age Factors; Aged; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Chi-Square Distribution; Disease Progression; Double-Blind Method; Female; Fluoroquinolones; Forced Expiratory Volume; Humans; Logistic Models; Lung; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Risk Factors; Severity of Illness Index; Sputum; Time Factors; Treatment Failure | 2015 |
Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Sputum; Treatment Outcome | 2016 |
Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study.
Topics: Administration, Intravenous; Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Intraabdominal Infections; Male; Moxifloxacin; Prospective Studies | 2018 |
20 other study(ies) available for moxifloxacin and amoxicillin-potassium clavulanate combination
| Article | Year |
|---|---|
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluoroquinolones; France; Germany; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2003 |
In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Fluoroquinolones; Humans; In Vitro Techniques; Inhibitory Concentration 50; Linezolid; Meropenem; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Oxazolidinones; Pyrrolidines; Quinolines; Quinolones; Thienamycins | 2006 |
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Azithromycin; beta-Lactamases; Cefpodoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Ketolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Selection, Genetic | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria, Anaerobic; beta-Lactamases; Cefoxitin; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Penicillins; Quinolines | 2007 |
Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Blood; Clindamycin; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Anaerobic Bacteria; Hemin; Humans; Ketolides; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Periodontitis; Quinolines; Saliva; Vitamin K | 2007 |
Trimethoprim/sulfamethoxazole resistance in urinary tract infections.
Topics: Adolescent; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Aza Compounds; Ceftriaxone; Drug Resistance, Microbial; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections; Young Adult | 2009 |
Abuse of antibiotic prophylaxis in third molar surgeries.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Fluoroquinolones; Humans; Molar, Third; Moxifloxacin; Postoperative Complications; Quinolines; Randomized Controlled Trials as Topic; Surgical Wound Infection; Time Factors; Tooth Extraction | 2009 |
Antimicrobial susceptibility of moxifloxacin against gram-negative enteric rods from colombian patients with chronic periodontitis.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Chi-Square Distribution; Chronic Periodontitis; Ciprofloxacin; Colombia; Dental Plaque; Enterobacteriaceae; Female; Fluoroquinolones; Gram-Negative Facultatively Anaerobic Rods; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pseudomonas; Quinolines; Statistics, Nonparametric | 2010 |
Antibiotic resistance of subgingival species in chronic periodontitis patients.
Topics: Adult; Aged; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin Resistance; Anti-Infective Agents; Aza Compounds; Bacteriological Techniques; beta-Lactam Resistance; Chronic Periodontitis; Clindamycin; Colombia; Dental Plaque; Drug Resistance, Bacterial; Female; Fluoroquinolones; Fusobacterium nucleatum; Gingival Hemorrhage; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Periodontal Attachment Loss; Periodontal Pocket; Porphyromonas gingivalis; Prevotella; Quinolines | 2010 |
Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Aza Compounds; Bacteremia; Drug Resistance, Bacterial; Drug Utilization; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Spain; Young Adult | 2011 |
Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.
Topics: Acetamides; Actinobacillus Infections; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Capnocytophaga; Coculture Techniques; Coinfection; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Linezolid; Metronidazole; Microbial Interactions; Minocycline; Moxifloxacin; Oxazolidinones; Penicillin G; Peptostreptococcus; Peri-Implantitis; Periodontitis; Quinolines; Sulbactam | 2011 |
Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quinolines | 2012 |
Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Cohort Studies; Costs and Cost Analysis; Female; Fluoroquinolones; Follow-Up Studies; Forced Expiratory Volume; Health Care Costs; Hospitalization; Humans; Male; Middle Aged; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Failure; Treatment Outcome | 2013 |
Salvage therapy for multidrug-resistant tuberculosis.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Capreomycin; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Male; Moxifloxacin; Mycobacterium tuberculosis; Retrospective Studies; Rifampin; Salvage Therapy; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
Laser receptive polyelectrolyte thin films doped with biosynthesized silver nanoparticles for antibacterial coatings and drug delivery applications.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Dextran Sulfate; Drug Delivery Systems; Erythromycin; Fluoroquinolones; Lasers; Metal Nanoparticles; Moxifloxacin; Plant Extracts; Plant Leaves; Polyamines; Quinolines; Silver; Violaceae | 2013 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections.
Topics: Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Centers for Disease Control and Prevention, U.S.; Drug Utilization; Female; Fluoroquinolones; Humans; Inappropriate Prescribing; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Outpatients; Practice Patterns, Physicians'; Respiratory Tract Infections; Retrospective Studies; United States | 2015 |
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Case-Control Studies; Ciprofloxacin; Female; Fluoroquinolones; Humans; Incidence; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Ofloxacin; Peripheral Nervous System Diseases; Risk Factors; Sex Factors; United Kingdom | 2019 |
Antibiotic Resistance among Fusobacterium, Capnocytophaga, and Leptotrichia Species of the Oral Cavity.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Capnocytophaga; Ciprofloxacin; Clindamycin; Doxycycline; Drug Resistance, Bacterial; Fusobacterium; Humans; Leptothrix; Leptotrichia; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Periodontal Diseases | 2023 |